University of Wisconsin Foundation Takes $1.77 Million Position in Sarepta Therapeutics, Inc. $SRPT

Key Points

• The University of Wisconsin Foundation purchased 27,717 shares of Sarepta Therapeutics, valued at approximately $1.77 million, making it the foundation's 8th largest holding.
• Sarepta's stock has experienced significant analyst activity, with targets ranging from $13 to $43.50 and a general consensus rating of "Hold."
• The company's recent earnings report showed a significant revenue increase of 68.4% year-over-year, with EPS of $2.02 exceeding consensus estimates by $1.13.

University of Wisconsin Foundation purchased a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 27,717 shares of the biotechnology company's stock, valued at approximately $1,769,000. Sarepta Therapeutics makes up about 1.4% of University of Wisconsin Foundation's investment portfolio, making the stock its 8th biggest position.

A number of other hedge funds also recently bought and sold shares of the business. EP Wealth Advisors LLC lifted its holdings in shares of Sarepta Therapeutics by 2.2% in the 4th quarter. EP Wealth Advisors LLC now owns 4,988 shares of the biotechnology company's stock worth $606,000 after acquiring an additional 105 shares during the last quarter. Virtus ETF Advisers LLC increased its stake in Sarepta Therapeutics by 6.6% in the 4th quarter. Virtus ETF Advisers LLC now owns 2,809 shares of the biotechnology company's stock worth $342,000 after buying an additional 174 shares during the period. Wealth Enhancement Advisory Services LLC increased its stake in Sarepta Therapeutics by 4.9% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 4,699 shares of the biotechnology company's stock worth $571,000 after buying an additional 218 shares during the period. UMB Bank n.a. increased its stake in Sarepta Therapeutics by 53.0% in the 1st quarter. UMB Bank n.a. now owns 797 shares of the biotechnology company's stock worth $51,000 after buying an additional 276 shares during the period. Finally, State of Alaska Department of Revenue increased its stake in Sarepta Therapeutics by 2.6% in the 1st quarter. State of Alaska Department of Revenue now owns 11,175 shares of the biotechnology company's stock worth $713,000 after buying an additional 285 shares during the period. Hedge funds and other institutional investors own 86.68% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. UBS Group reaffirmed a "neutral" rating on shares of Sarepta Therapeutics in a research note on Monday, July 21st. Wolfe Research assumed coverage on shares of Sarepta Therapeutics in a research note on Tuesday, June 17th. They issued a "peer perform" rating on the stock. Piper Sandler raised their price target on shares of Sarepta Therapeutics to $15.00 and gave the stock a "neutral" rating in a research note on Tuesday, July 29th. Baird R W downgraded shares of Sarepta Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Friday, July 18th. Finally, BMO Capital Markets raised their price target on shares of Sarepta Therapeutics from $25.00 to $50.00 and gave the stock a "market perform" rating in a research note on Tuesday, July 29th. Eight equities research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and six have issued a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $43.50.

Sarepta Therapeutics Stock Down 1.1%

Shares of NASDAQ:SRPT traded down $0.19 during trading on Friday, reaching $18.15. The stock had a trading volume of 2,249,111 shares, compared to its average volume of 6,251,111. Sarepta Therapeutics, Inc. has a one year low of $10.41 and a one year high of $140.10. The company has a market capitalization of $1.77 billion, a P/E ratio of -20.84 and a beta of 0.46. The company has a current ratio of 2.89, a quick ratio of 1.81 and a debt-to-equity ratio of 0.84. The firm's 50-day simple moving average is $17.76 and its 200 day simple moving average is $48.09.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 earnings per share for the quarter, beating analysts' consensus estimates of $0.89 by $1.13. Sarepta Therapeutics had a negative net margin of 2.34% and a negative return on equity of 1.03%. The business had revenue of $611.09 million for the quarter, compared to analysts' expectations of $530.66 million. During the same period last year, the business earned $0.07 EPS. The company's revenue was up 68.4% compared to the same quarter last year. As a group, research analysts expect that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current fiscal year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.